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Abstract
 
Human immunoglobulin (Ig)A exists in blood as two isotypes, IgA1 and IgA2, with IgA2
present as three allotypes: IgA2m(1), IgA2m(2), and IgA2m(n). We now demonstrate that re-
combinant, chimeric IgA1 and IgA2 differ in their pharmacokinetic properties. The major
pathway for the clearance of all IgA2 allotypes is the liver. Liver-mediated uptake is through
the asialoglycoprotein receptor (ASGR), since clearance can be blocked by injection of excess
galactose-Ficoll ligand and suppressed in ASGR-deficient mice. In contrast, only a small per-
centage of IgA1 is cleared through this pathway. The clearance of IgA1 lacking the hinge re-
gion with its associated O-linked carbohydrate was more rapid than that of wild-type IgA1.
IgA1 and IgA2 that are not rapidly eliminated by the ASGR are both removed through an un-
defined ASGR-independent pathway with half-lives of 14 and 10 h, respectively. The rapid
clearance of IgA2 but not IgA1 through the liver may in part explain why the serum levels of
IgA1 are greater than those of IgA2. In addition, dysfunction of the ASGR or altered N-linked
glycosylation, but not 
 
O
 
-glycans, that affects recognition by this receptor may account for the
elevated serum IgA seen in liver disease and IgA nephropathy.
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Introduction
 
An increased concentration of IgA is often seen in the se-
rum of patients with alcoholic liver disease (ALD)
 
1
 
 and IgA
nephropathy (IgAN) (1–4). The factors responsible for the
elevated levels of serum IgA in these disorders remain to be
elucidated. In ALD, changes in subclass distribution and
molecular form of IgA and in the deposition of IgA in var-
ious tissues have been reported (2, 5–7). Aberrant IgA gly-
cosylation and defective clearance from plasma by the liver
are implicated in the pathogenesis of IgAN (8–10).
In humans, IgA is the predominant immunoglobulin
synthesized and exceeds the combined total of all the other
immunoglobulin classes (11). It is estimated that 66 mg of
IgA/kg of body weight is produced daily compared with
34 mg of IgG and 7.9 mg of IgM. However, in normal hu-
man serum the IgA concentration is about one fifth that of
IgG. Most of the IgA synthesis occurs in the lamina propria
of the mucosal surfaces. The IgA synthesized in the lamina
propria is transported into the external secretions where it
is the most abundant immunoglobulin.
Human IgA exists as two isotypes, IgA1 and IgA2;
 
three allotypes of IgA2 have been described: IgA2m(1),
IgA2m(2), and the more recently discovered novel allotype
IgA2(n) (11–13). The major difference between the IgA1
and IgA2 subclasses is a 13–amino acid deletion in the IgA2
hinge region. The IgA1 hinge region contains three to five
O-linked carbohydrate moieties lacking in IgA2. IgA1 has
two N-linked carbohydrate addition sites in C
 
H
 
2 (Asn
 
263
 
)
and in C
 
H
 
3 (Asn
 
459
 
). All IgA2 allotypes have two additional
N-linked sites, in C
 
H
 
1 (Asn
 
166
 
) and in C
 
H
 
2 (Asn
 
337
 
). The
IgA2m(2) and the IgA2(n) allotypes have a fifth N-linked
site in C
 
H
 
1 (Asn
 
211
 
). The variations in the glycosylation
structure of the different forms of IgA may affect their bio-
logical properties.
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The importance of the Fc receptors in antibody function
in vivo has been recently reviewed (14). Studies using
myeloma IgA have implicated both the polymeric Ig re-
ceptor (pIgR) and the asialoglycoprotein-binding receptor
(ASGR) expressed by the liver in the regulation of serum
IgA levels (for reviews, see references 4 and 11). A limited
number of studies in humans suggests that pIgR on hepato-
cytes may not play an important role in regulating the se-
rum IgA levels (2, 4). In rats and rabbits, the pIgR on hepa-
tocytes has been shown to bind circulating polymeric IgA
and mediate its transport into bile. In mice, the hepatic
pIgR is less efficient in IgA clearance from plasma (15).
The ASGR expressed by the hepatocytes of various animal
species has also been implicated in the clearance of circu-
lating serum IgA (11). However, none of these studies has
investigated the contribution of the isotype and allotype
differences of IgA to its in vivo metabolism and biodistri-
bution.
With the advances in molecular biology, it is now possi-
ble to produce well-characterized IgA proteins differing
only in their isotype and allotype. In this study, we have in-
vestigated in mice the physiology of IgA proteins of differ-
ent isotype and allotype with an identical L chain and vari-
able region: all proteins were produced in Sp2/0 cells. Our
studies have shown that the ASGR present in the liver rap-
idly clears all three allotypes of IgA2. There is also some
clearance of IgA1 through the ASGR, but this clearance
pathway makes only a minor contribution to its serum half-
life. The O-linked carbohydrates present in the hinge do
not appear to be responsible for the rapid clearance, since
hinge-deleted IgA1 was cleared more rapidly than the na-
tive molecule. Thus, our results suggest that the N-linked
carbohydrates in IgA play an important role in the clear-
ance from blood and uptake by the liver. In addition, our
studies show the differences in the clearance of IgA1 and
IgA2 and may provide insights into the cause of the altered
abundance in different diseased states.
 
Materials and Methods
 
Reagents and Cells.
 
Restriction endonucleases and molecular
cloning enzymes were obtained from either New England
Biolabs, Inc., Amersham Pharmacia Biotech, Stratagene, or
Promega, and were used according to the manufacturers’ sugges-
tions. [
 
35
 
S]Methionine was obtained from ICN Research Prod-
ucts. Carrier-free Na
 
125
 
I was purchased from NEN Life Science
Products. Iodobeads used for iodination were purchased from
Pierce Chemical Co. Sp2/0 and transfectants were cultured in
IMDM containing 5% bovine calf serum (BCS; Hyclone Labora-
tories).
 
Production of Wild-Type and Carbohydrate Mutants of IgA.
 
The
generation of 
 
a
 
1, 
 
a
 
2m(1), 
 
a
 
2m(2), and 
 
a
 
2(n) H chain genes
containing a murine V
 
H
 
 region specific for the hapten dansyl was
described previously (16). The generation of IgA1 lacking the
N-linked carbohydrate was described by Chuang and Morrison
(17). IgA1 lacking a hinge region was generated by PCR using
the 
 
a
 
1 gene in the Bluescript
 
1
 
 as a template (Stratagene). The
PCR product was generated using the M13 reverse primer
and the oligomer 5
 
9
 
-GTCCTCGAGGGGGAACTGGAGTG-
GAGAGATGG-3
 
9
 
 (the underlined letters indicate the XhoI
site). The PCR product was cloned into the TA vector (Invitro-
gen), and the sequence was confirmed by sequencing. A 737-bp
XhoI-SalI fragment was cloned into the wild-type 
 
a
 
1.
Cells expressing the desired protein were produced by elec-
troporation into Sp2/0 cells expressing the dansyl-specific chi-
meric 
 
k
 
 L chain gene as described previously (13). Transfectants
were selected in medium containing 15 
 
m
 
g/ml hypoxanthine,
250 
 
m
 
g/ml xanthine, and 6 
 
m
 
g/ml mycophenolic acid. Surviving
colonies were screened for IgA production by ELISA using mi-
crotiter plates coated with dansyl coupled to BSA to capture IgA
and an alkaline phosphatase–conjugated goat anti–human 
 
k
 
 to
detect bound IgA. Color was developed by adding 
 
p
 
-nitrophenyl
phosphate (Sigma-Aldrich), and the absorbance at 410 nM was
determined using a microplate reader (model MR 700; Dyna-
tech). Clones producing the highest quantities of IgA were ex-
panded in IMDM containing 10% (vol/vol) BCS.
 
Large Scale Cell Culture and Purification of IgA Antibodies.
 
Transfectomas were cultured in roller bottles (Becton Dickinson)
in IMDM supplemented with 1% BCS (Hyclone) and 6 mM
Glutamax (GIBCO BRL). Supernatants were filtered to remove
any cells and cell debris and supplemented with 10 mM phos-
phate buffer, pH 6.8, 0.45 M NaCl, 0.02 M EDTA, and 0.02%
NaN
 
3
 
. Proteins were purified by affinity chromatography using
AH-Sepharose beads coupled with the dansyl isomer 2-dimeth-
yl-aminonaphthalene-5-sulfonyl chloride (Molecular Probes).
Bound antibodies were eluted with 
 
N
 
-(5-carboxy-pentyl)-2-
dimethyl-aminonaphthyl-5-sulfonamide. The eluted proteins
were concentrated and the hapten was removed by extensive di-
alysis against Tris buffer, pH 7.8, containing 0.45 M NaCl and
0.02% NaN
 
3
 
. The concentration of proteins was determined with
the bicinchoninic acid assay (Pierce Chemical Co.) or by com-
parison with a standard of known concentration after SDS-PAGE
and staining with Coomassie blue.
 
Radioiodination.
 
Purified IgA was radiolabeled with carrier-
free Na
 
125
 
I (NEN Life Science Products) using Iodobeads (Pierce
Chemical Co.). In brief, 100 
 
m
 
Ci 
 
125
 
I diluted in 20 
 
m
 
l of phos-
phate buffer (pH 7.0) was added to prewashed and dried Iodo-
beads. After 5 min, 25 
 
m
 
g of IgA was added to the tube and the
reaction mixture was incubated at room temperature for 20 min.
To stop the reaction, the bead was removed and rinsed with 20
 
m
 
l of phosphate buffer. The iodinated protein solution was passed
twice over Sephadex G-10 spin column to remove the free 
 
125
 
I.
Under these conditions, the specific activity of the iodinated IgA
was between 7 
 
3 
 
10
 
5
 
 and 1.2 
 
3 
 
10
 
6
 
 cpm/
 
m
 
g. The TCA-precip-
itable radioactivity for the different IgA preparations varied be-
tween 90 and 98%.
 
Reduction and Alkylation of IgA.
 
Purified and radiolabeled IgA
(5 g) in 0.3 M Tris buffer (pH 8.6) was reduced by slow addition
of 0.5 M 1,4-dithiothreitol to a final concentration of 0.05 M.
The IgA was kept stirring gently in an ice bath for 30 min. The
IgA was alkylated by slow addition of 0.5 M 2-iodoacetamide to
a final concentration that is 50% molar excess of the dithiothrei-
tol. The reaction solution was maintained stirring under a gentle
stream of nitrogen. After 2 h, the IgA preparation was passed over
P6 BioSpin (Bio-Rad Laboratories) column preequilibrated with
borate-buffered saline (pH 8.0).
 
Analysis of IgA Proteins.
 
Purified proteins were analyzed by
SDS-PAGE under nonreducing conditions in 5% phosphate gels
to determine the covalent assembly pattern, and under reducing
conditions in 12.5% Tris-glycine gels to determine the molecular
weight of the H, L, and J chains. The size of IgA in each prepara-
tion reflecting both the covalent and noncovalent interactions 
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was determined with 2–16% polyacrylamide gradient slab gels
(PAA 2/16; Amersham Pharmacia Biotech), prerun for 30 min at
125 V with 0.09 M Tris, 0.08 M boric acid, 0.003 M EDTA, pH
8.35. The samples for analysis were diluted by adding a 40% su-
crose solution in a volume equal to one quarter of the sample
volume, and were loaded in every other slot. After electrophore-
sis at 70 V for 20 min, electrophoresis continued for a total of
1,800 V-h. The gel was then fixed in 10% sulfosalicylic acid for
10 min and stained in 0.1% Coomassie blue R-250 (Bio-Rad
Laboratories) in 25% methanol, 10% acetic acid solution and
destained by diffusion in 5% acetic acid, 20% methanol solution.
Each gel was sliced vertically into channels, and each channel was
cut into 2-mm slices that were analyzed for radioactivity.
 
Animal Experiments.
 
Female 2–3-mo-old C57BL/6J mice
(16–20 g) were purchased from The Jackson Laboratory. Pairs of
mice with homozygous disruption of ASGR2 (B6,129-ASGR2)
were bred in house. All of the animal experiments were carried
out in accordance with approved institutional guidelines (Animal
Welfare Assurance No. 39222) at the Department of Pathology,
Rhode Island Hospital, Brown University. Radioiodinated IgA
(1 
 
m
 
g) diluted in 0.2 ml of PBS containing 0.2% HSA (Baxter)
was injected into the tail vein. Blood samples of 20 
 
m
 
l obtained
with heparin-treated micropipettes from the retroorbital venous
plexus at different time intervals were expelled into 0.5 ml PBS
in 12 
 
3
 
 75-mm glass tubes. An equal volume of 20% TCA was
added and after overnight incubation at 4
 
8
 
C, the tubes were cen-
trifuged at 2,000 
 
g
 
 for 30 min. The TCA pellet and supernatant
were counted separately in a gamma counter (1260-Multigamma
II; LKB). The values of TCA-precipitable radioactivity remain-
ing in the blood were used to derive the clearance curves; the
zero time value was extrapolated from the first three data points
(1, 2.5, and 5 min) by linear regression analysis. The means and
standard deviations were calculated for each time point, plotted,
and analyzed by graphic peeling (18). The elimination rate con-
stant (
 
K
 
el
 
) was derived from the slope of the curve (slope
 
 5 
 
K
 
el
 
/
2.303), which was calculated by regression analysis in a worksheet
program (Analytical Tools, Microsoft Excel, Microsoft Office
97). The half-life (
 
t
 
1/2
 
) of circulating IgA was determined from
the expression, 
 
t
 
1/2
 
 
 
5 
 
0.693/
 
K
 
el
 
.
In the blocking studies, 1 mg of galactose-Ficoll (19) was
mixed with 1 
 
m
 
g of IgA. The mixture was introduced into the
tail vein, and the blood samples were collected and measured as
described (20).
The organ distribution of the IgA was determined 10 and 60
min after injection of radioactive protein. The mice were anes-
thetized with pentobarbital followed immediately by incision of
the thoracic cavity. The heart, kidneys, liver, and lungs were ren-
dered free of blood by perfusion of 10 ml of saline through the
left ventricle. All of the excised organs and tissues were weighed
before measurement of radioactivity. The amount of radioactivity
within each organ was determined in an LKB gamma scintillator,
and the values were expressed as a percentage of the total amount
administered or as a percentage of the dose per gram of tissue.
 
Data Analysis.
 
Student’s 
 
t
 
 test or analysis of variance was used
to determine statistical significance of differences between mean
results in control and experimental groups.
 
Results
 
Characterization of Recombinant IgA Antibodies.
 
The pro-
duction of the transfectants secreting IgA1, IgA2m(1),
IgA2m(2), and IgA2m(n) was described previously (16).
When the transfectants were cultured in medium contain-
ing [
 
35
 
S]methionine for 16 h, the secreted IgA was immu-
noprecipitated and analyzed by SDS-PAGE under non-
reducing conditions. IgA1 and IgA(n) showed two
predominant bands corresponding to the dimeric (dIgA)
and monomeric (mIgA) forms of IgA and minor bands cor-
responding to HL and dIgA lacking L chains (data not
shown). As reported previously, IgA2m(1) was present
mostly as L, L
 
2
 
, H
 
2
 
, and H
 
4
 
J molecules lacking HL disulfide
bonds. IgA2m(2) showed multiple bands corresponding to
free H and L chains and H
 
2
 
L as well as mIgA and dIgA.
When the proteins were analyzed by SDS-PAGE in 12.5%
gels under reducing conditions, all contained 
 
a
 
 H chains, 
 
k
 
L chain, and J chain (data not shown).
Although in most laboratory animals, serum IgA exists
predominantly as covalent polymers, 
 
.
 
90% of human se-
rum IgA is monomer (12). However, monomeric human
serum IgA has been shown to form polymers (mainly
dimer and smaller amounts of trimer and tetramers) held
together by noncovalent interactions that can be disrupted
by SDS. To determine the molecular form of the anti-dan-
syl IgA under nondenaturing conditions, the affinity-puri-
fied proteins were radioiodinated and analyzed in native
2–16% polyacrylamide gradient gels. Dimeric IgA was the
predominant molecular form (51–75%) in all of the prepa-
rations (Fig. 1 and Table I). Only IgA2m(2) had a signifi-
cant amount (34%) of a polymeric form larger than a
Figure 1. Analysis of IgA1, IgA2m(1), IgA2m(2), and IgA2(n) by na-
tive gradient PAGE. To determine the monomer, dimer, and polymer
composition of IgA proteins, proteins were analyzed on 2–16% native
polyacrylamide slab gels in the absence of any denaturant. An autoradio-
gram of each IgA preparation shows the distribution of radioactivity in
the gel channel. For quantitative analysis, the gel channels were sliced and
counted as described in Materials and Methods. Monomeric IgA migrates
furthest and localizes toward the bottom of the gel between 60 and 80%
of the gel length. IgA dimer migrates and localizes between 35 and 50%
of the gel length. 
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dimer. IgA1 and IgA2m(1) had a significant and similar
amount (25%) of the monomeric form.
 
Blood Clearance of IgA1 and IgA2 Antibodies.
 
To deter-
mine whether isotypic and allotypic differences influence
the in vivo survival of IgA, we studied the blood clearance
of 1 
 
m
 
g of 
 
125
 
I-labeled IgA1 or IgA2 injected into the tail
vein of C57BL/6 mice. At timed intervals after injection,
blood was collected from the retroorbital plexus and the
TCA-precipitable counts remaining in circulation were de-
termined. Although both IgA1 and IgA2 cleared rapidly,
IgA2 was eliminated more rapidly from the circulation than
IgA1 (Fig. 2). Half of the IgA1 was removed from the
blood in 
 
z
 
35 min. In contrast, half of IgA2m(1), IgA2m(2),
and IgA2m(n) was removed in 5, 4, and 3 min, respectively.
 
Tissue Distribution of IgA1 and IgA2.
 
To assess the fate
of the circulating IgA, the tissue distribution of radioactiv-
 
ity was examined at 10 and 60 min after intravenous ad-
ministration (Table II). At 10 min after injection, the liver
was the principal organ mediating IgA removal from the
circulation. At that time, 10% of the IgA1 and 
 
z
 
30% of
IgA2m(1) and IgA2m(2) and 41% of IgA2(n) were found
per gram of liver. At 60 min after injection, the amount of
IgA1 in the liver remained relatively constant, whereas the
amount of IgA2 decreased to 15–18% per gram of liver.
These results are consistent with the kinetics of IgA1 and
IgA2 disappearance from the blood and suggest that IgA2 is
rapidly removed and degraded by the liver. By 60 min,
 
z
 
12% of IgA2 and 2.5% of IgA1 were found per gram of
gastrointestinal tract. The increase in radioactivity in the
gastrointestinal tract correlates with an increase in the
TCA-soluble radioactivity in the blood, suggesting that
the radioactivity found in the gastrointestinal tract may rep-
resent the excretion of the degraded products.
 
Influence of IgA Size on Clearance.
 
Dimeric but not mo-
nomeric IgA is removed from circulation through binding
to the pIgR on rodent hepatocytes (4, 11, 15). Since IgA
preparations used in these studies contained different
amounts of dimers and monomers, the clearance of native
monomers and dimers was characterized (21). Sequential
plasma specimens obtained at 1, 5, 10, and 30 min, 1, 2, 4,
8, and 24 h after injection of iodinated IgA1 were analyzed
by gradient PAGE (Fig. 3, A and B). The radioactivity in
the bands was quantified by cutting the bands and count-
ing, and the percentage of the radioactivity remaining in
the circulation was plotted against time (Fig. 3 C). Dimeric
IgA1 was cleared more rapidly than monomeric IgA. Be-
cause only single point measurements were used for these
clearance curves, statistical analysis of the components was
not conducted. Clearance of the dimer was biphasic, with
an initial rapid phase in which 69% of IgA1 was cleared
with an estimated half-life (
 
t
 
1/2
 
) of 8.3 min and a slow phase
in which 31% of IgA1 was cleared with a 
 
t
 
1/2
 
 of 3.6 h. A
similar initial phase was observed for monomeric IgA1,
with 67% removed with a 
 
t
 
1/2
 
 of 98 min; the rate of mono-
mer clearance in the second phase was much slower, with
33% removed with a 
 
t
 
1/2
 
 of 22.8 h.
To further investigate the influence of size on IgA clear-
ance, radiolabeled IgA1 and IgA2 preparations were mildly
reduced and alkylated to enrich for monomeric forms. As
presented in Table I, the amount of monomer in the re-
 
Table I.
 
Percentage of Molecular Forms in the Native and Reduced and Alkylated IgA Proteins
 
Native Reduced and alkylated
Molecular form IgA1 IgA2m(1) IgA2m(2) IgA2m(n) IgA1 IgA2m(1) IgA2m(2) IgA2m(n)
pIgA 10.5 7 34 18.3 – – – –
dIgA 61 68.5 51.2 75 29 68 38 24
mIgA 25 22.5 12.7 5.6 61 27 59 51
Native and reduced and alkylated IgA proteins were analyzed by PAGE in 2–16% native gradient gels and analyzed by autoradiography.
 
*
 
Polymeric (pIgA), dimeric (dIgA), and monomeric (mIgA).
Figure 2. Kinetics of 60-min serum clearance of anti-dansyl IgA1,
IgA2m(1), IgA2m(2), and IgA2(n) in C57BL/6 mice. 1 mg of each of the
125I-labeled proteins was injected into the tail vein. At indicated times af-
ter injection, aliquots of blood obtained from the retroorbital venous
plexus were precipitated with 10% TCA to determine protein-bound ra-
dioactivity. The first three data points were used to extrapolate the 100%
value at zero time point using linear regression analysis. Each data point
represents the mean 6 SD of three mice. Data are representative of mul-
tiple experiments performed using different preparations of IgA contain-
ing varying ratios of polymer to monomer. The superimposed dotted
gridlines highlight the time (t50%) required for the disappearance of 50% of
the administered dose. 
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duced and alkylated IgA preparations, determined by elec-
trophoresis in 2–16% gels, was as follows: 62% for IgA1,
28% for IgA2m(1), 59% for IgA2m(2), and 51% for IgA2(n).
Only the IgA2m(1) failed to be enriched for monomeric
IgA. The reduced-alkylated IgA preparations were injected
into C57BL/6 mice, and the clearance was monitored (Fig.
4 A). Enrichment for monomeric IgA did not significantly
slow the clearance rate or alter the clearance patterns (com-
pare Fig. 2 and Fig. 4 A). If anything, enrichment for
monomers increased the hepatic clearance of IgA2 (com-
pare Table I and Fig. 4 B). These results indicate that the re-
moval of IgA2 from the circulation is not determined by its
polymerization state and suggest that the pIgR does not play
a primary role in the clearance of human IgA2 in mice.
Table II. Distribution of IgA in Tissues 10 and 60 min after Injection
IgA1 IgA2m(1) IgA2m(2) IgA2m(n)
Tissue 10 min 60 min 10 min 60 min 10 min 60 min 10 min 60 min
Gastrointestinal 0.9 6 0.1 2.4 6 1.4 0.6 6 0.1 11.8 6 1.4 1.5 6 0.6 11.5 6 4.4 0.6 6 0.1 13.1 6 2.9
Heart* 1.8 6 0.9 1.1 6 0.6 0.7 6 0.1 1.2 6 0.3 0.7 6 0.1 0.9 6 0.3 0.6 6 0.0 1.1 6 0.2
Kidney* 5.5 6 0.6 4.9 6 0.1 4.1 6 0.9 5.3 6 1.8 6.6 6 1.3 8.4 6 1.4 2.8 6 0.6 4.9 6 2.8
Liver* 9.7 6 0.1 8.7 6 0.2 31.6 6 2.7 17.9 6 3.2 38.8 6 3.4 15.0 6 2.8 39.6 6 2.8 17.0 6 2.3
Lungs* 2.0 6 1.0 2.0 6 0.4 1.0 6 0.2 1.6 6 0.4 1.0 6 0.2 1.5 6 0.1 1.3 6 0.3 1.1 6 0.8
Spleen* 4.1 6 0.6 4.0 6 0.9 1.2 6 1.3 2.4 6 1.1 1.6 6 0.4 2.8 6 0.6 2.8 6 0.3 2.1 6 0.7
Data represent percentage of administered dose per gram of tissue. Each value is the mean 6 SD for a group of three mice.
*Rendered blood free by cardiac perfusion.
Figure 3. Analysis by electrophoresis in
native gradient polyacrylamide gels (2–16%)
of the disappearance from the circulation of
monomeric and dimeric IgA1. Purified
IgA1 (0 min) and plasma samples obtained
during the first 30 min after injection (A) or
1 and 24 h after injection (B) were fraction-
ated on native gradient gels and analyzed by
autoradiography (exposures: [A] 36 h; [B]
7 d). (C) Clearance of dimeric and mono-
meric IgA determined by the measurement
of the radioactivity present in plasma that
localized at 35–50% (dimer) or 60–80%
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Role of the ASGR in IgA Elimination. To elucidate the
mechanisms that mediate the rapid clearance from the cir-
culation and the rapid hepatic uptake of the IgA2 allotypes,
we examined the potential role of the liver ASGR. In a se-
ries of experiments, we determined the kinetics of clear-
ance of 1 mg of IgA in the presence of excess (1 mg) of the
specific ASGR ligand, galactose-Ficoll (Fig. 5). The pres-
ence of galactose-Ficoll as a receptor competitor did not
significantly affect the clearance of IgA1, but it did drasti-
cally prolong the clearance of all three IgA2 allotypes. To
confirm the role of ASGR in mediating the elimination of
circulating IgA2, the clearance of IgA1 and IgA2 allotypes
in ASGR knockout mice (ASGR2/2) was determined (Fig.
5). The elimination patterns of the IgA2 allotypes in
ASGR2/2 were indistinguishable from the clearance curves
in the presence galactose-Ficoll. Interestingly, blocking or
inactivating the ASGR resulted in elimination of all three
IgA2 allotypes in a pattern similar to IgA1.
The hepatic uptake data at 10 min (Fig. 6) confirmed a
role for the ASGR in the clearance of IgA. Galactose-Ficoll
significantly (P 5 0.0028) reduced the hepatic uptake of
IgA1 (from 10 to 7.8% of administered dose) in C57BL/6
mice. Galactose-Ficoll had an even more dramatic effect on
hepatic uptake of all three IgA2 allotypes. Similar decreased
hepatic uptake of all three IgA2 allotypes was also observed
in ASGR2/2 mice. Thus, both blocking and inactivating
the receptor demonstrate that the hepatic ASGR plays a
major role in the rapid elimination of human IgA2 from
the circulation.
Influence of the ASGR on the Catabolism of IgA2. To
further explore the role of the ASGR in the catabolism of
IgA2, the 24-h clearance of IgA2m(1) and IgA2m(2) in
wild-type and ASGR2/2 mice was compared. The 24-h
disappearance curves for IgA2m(1), Fig. 7 A, were com-
posed of three exponential components, as determined by
graphic peeling in conjunction with linear regression analy-
sis. There is a significant difference (P 5 0.0016) in the
amount of IgA2m(1) removed from circulation in the first
rapid phase, with 43.7 6 5.1% rapidly removed in wild-
type compared with 16.8 6 2.1% in ASGR2/2 mice. In
the second intermediate phase, there was no significant dif-
ference between the amount of IgA2m(1) in wild-type
(39.0  6  4.0%) and ASGR2/2 (37.0 6 2.5%) mice. The de-
crease in the amount of IgA2m(1) removal in the first phase
in the ASGR2/2 mice is accompanied by an increase in the
amount slowly metabolized in the terminal phase (from
17.4 6 1.2% in wild-type to 46.3 6 2.7% in ASGR2/2
mice; P 5 0.0004). Interestingly, during this phase a similar
rate of clearance was seen in the ASGR2/2 and wild-type
mice (9.6 6 0.2 h in wild-type vs. 10.5 6 0.8 h in
ASGR2/2). The rapid increase of TCA-soluble radioactiv-
ity during the first 4 h (Fig. 7 A, insert) seen in the wild-
type mice but not in ASGR2/2 mice during this period is
consistent with the elimination pattern.
A significant (P , 0.0001) difference was also seen in the
clearance of IgA2m(2) in wild-type and ASGR2/2 mice. In
wild-type mice, the majority of the IgAm(2) (84.5 6 1.3%)
was eliminated from the circulation with a t1/2 5 3.0 6 0.2
min (Fig. 7 B), whereas in ASGR2/2 mice only 26.9 6
4.5% was rapidly removed with a t1/2 5 5.3 6 2.5 min.
Similar to what was observed with IgA2m(1), in ASGR2/2
mice there was a significant increase (P  ,  0.0001) in
amount of IgA clearing slowly in the terminal phase (from
7.3 6 0.1 to 63.7 6 4.9%). Again, a similar rate of elimina-
tion during this phase was observed in wild-type (t1/2 5
9.5 6 0.1 h) and ASGR2/2 (t1/2 5 9.2 6 0.5 h) mice. The
high rate of uptake and catabolism of IgA2m(2) in wild-
type mice during the initial phase is accompanied by a dra-
matic increase in TCA-soluble material, reaching 60% of
the radioactivity in the blood sample at 8 h (Fig. 7 B, in-
sert). In contrast, there was little change in the amount of
TCA-soluble radioactivity in the blood samples of the
ASGR2/2 mice. These data suggest two pathways for IgA2
clearance: the first pathway is dependent on the ASGR and
Figure 4. Clearance and hepatic uptake of mildly reduced and alky-
lated IgA. (A) Clearance from the circulation of 1 mg of mildly reduced
and alkylated IgA1, IgA2m(1), IgA2m(2), and IgA2(n). The IgA remain-
ing in blood was determined as described in the legend to Fig. 3. Each
data point is the mean 6 SD for three normal mice. The superimposed
dotted gridlines highlight the time (t50%) required for the disappearance of
50% of the administered dose. (B) Hepatic uptake represented as the per-
centage of the injected dose of radioactivity measured in the blood-free
liver at 10 min.2177 Rifai et al.
leads to rapid hepatic uptake and degradation; the second
pathway is independent of the ASGR.
Role of Glycosylation in IgA1 Clearance. IgA1 contains
two N-linked glycosylation sites at positions Asn263 in CH2
and Asn459 in CH3 and five O-linked glycosylation sites in
the hinge region. Indeed, the terminal galactosyl-(b1–3)-
N-acetylgalactosamine residues present on the O-linked
sugars have been proposed as a ligand for the ASGR.
To determine the role of the O-linked carbohydrate
moieties in IgA1 clearance, the 24-h clearance of IgA1
lacking the hinge region (IgA1-dHinge) was determined.
Surprisingly, the clearance of IgA1-dHinge was signifi-
cantly (P 5 0.0006) more rapid than the clearance of IgA1,
with 51.8 6 1.4% of IgA1-dHinge cleared in the initial
rapid phase with a t1/2 5 6.1 6 1.7 min (Fig. 8) compared
with 36.2 6 2.3% of IgA1. The rapid elimination of IgA1-
dHinge was accompanied by the generation of circulating
TCA-soluble radioactivity (Fig. 8, insert). As a conse-
quence of the initial rapid elimination, significantly less (P ,
0.0001, 24.2 6 0.6%) of the IgA1-dHinge was eliminated
during the terminal phase than IgA1 (32.7 6 4.6%). Dur-
ing this phase, the IgA1-dHinge was also catabolized signif-
icantly (P 5 0.0035) faster (t1/2 5 10.3 6 0.6 h) than IgA1
(t1/2 5 14.5 6 1.4 h).
To determine if N-linked glycosylation plays a role in
the overall clearance of IgA1, the 24-h clearance of IgA1
lacking the N-linked carbohydrates (IgA1-Ca2,3) was de-
termined. Only 22.4 6 8.6% of IgA1-Ca2,3 was cleared in
Figure 5. Clearance from the serum of IgA1,
IgA2m(1), IgA2m(2), and IgA2(n) in ASGR2/2
knockout mice and in wild-type (WT) mice in the
presence and absence of the ASGR ligand galac-
tose-Ficoll. Trace amounts of radiolabeled IgA (1
mg) were injected into the tail vein of mice and at
the indicated time points, the IgA remaining in
blood was determined as described in the legend to
Fig. 3. To inhibit ASGR uptake in wild-type mice,
1 mg of galactose-Ficoll was simultaneously admin-
istered with the radiolabeled IgA.
Figure 6. Hepatic uptake of IgA2 in the presence of a saturating dose
of galactose-Ficoll in wild-type mice (WT) and in ASGR2/2 mice. The
hepatic content of radioactivity 10 min after injection is shown as the per-
centage of injected dose in blood-free liver. Each bar represents the mean 6
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the initial rapid phase compared with 36.2 6 2.3% of IgA1
in wild-type mice and 32.8 6 4.4% in ASGR2/2 mice.
The amount of IgA1-Ca2,3 (48.1 6 4.8%) clearing during
the terminal phase was similar to the amount of IgA1 clear-
ing during the terminal phase in ASGR2/2 (48.1 6 0.6%)
mice. During the terminal phase, IgA1-Ca2,3 (t1/2 5 16.2 6
2.0 h) and IgA1 in both wild-type (t1/2 5 14.5 6 1.4 h)
and ASGR2/2 mice (t1/2 5 13.5 6 0.7 h) were catabolized
at similar rates. The elimination pattern of the IgA1-Ca2,3
in wild-type mice was similar to that of IgA1 in ASGR2/2
mice. Taken together, these results suggest that the ASGR
may contribute to the rapid elimination of a portion of
IgA1 through the N-linked carbohydrate residues. More
importantly, the ASGR does not recognize the O-linked
galactosyl residues in the IgA1 hinge region.
Discussion
Human serum is 90% IgA1 and 10% IgA2 (11, 12).
However, in external secretions the proportion of IgA2 can
be as high as 50%. This characteristic distribution may re-
flect the fact that plasma cells in the bone marrow are the
source of serum IgA1 and plasma cells in the lamina propria
are the source of secreted IgA (22). A difference in the se-
rum half-life of different forms of IgA could also contribute
to these differences. Although several investigators have
studied the half-life of human IgA1, there are no studies
comparing the clearance kinetics of IgA1 and IgA2. Here,
we have compared the kinetics and pathways of clearance
of well-characterized IgA proteins of different isotypes and
allotypes that share an identical L chain and variable region
and are produced in the same Sp2/0 cells.
Our data demonstrate that all allotypes of IgA2 cleared
from blood of mice faster than IgA1. We found that IgA1
purified from human serum exhibited a rate and pattern of
clearance similar to those seen with recombinant IgA1 (data
Figure 7. Comparison of kinetics of serum clearance of IgA2m(1) and
IgA2m(2) in C57BL/6 (W.T.) and ASGR2/2 knockout mice. Radiola-
beled IgA2m(1) (A) or IgA2m(2) (B) was injected into the tail vein of
C57BL/6 or ASGR2/2 knockout mice. At the indicated time points, the
IgA remaining in the blood was determined as described in the legend to
Fig. 3. The amount of TCA-soluble material present in the blood at the
different times is shown in the insert. Each data point represents the mean 6
SD of three mice.
Figure 8. Influence of glycosylation on the blood removal and catabo-
lism of IgA1. The clearance in wild-type mice (W.T.) of intact IgA1,
IgA1 lacking N-linked glycosylation (IgA1-Ca2,3), and IgA1 lacking the
hinge with its associated O-linked oligosaccharides is compared with the
clearance of intact IgA1 in ASGR2/2 mice. The appearance of TCA-sol-
uble material (percentage of sample) radioactivity in the blood is shown in
the insert.2179 Rifai et al.
not shown). Hence, the slower rate of clearance of IgA1 is
not a result of either the chimeric structure of the IgA1 or
the expression system used for its production. Our results
are contrary to in vitro studies demonstrating higher bind-
ing of IgA1 than IgA2 to liver parenchymal and nonparen-
chymal cells (23, 24). As expected from previous experi-
mental and clinical studies (21, 25, 26), we found that the
dimeric form of IgA1 cleared more rapidly than the mono-
meric form (Fig. 3). However, enrichment of the mono-
meric molecular form of IgA2 by mild reduction and alky-
lation did not slow the rate of clearance (Fig. 4). Therefore,
the polymerization state of IgA2 is not the major determi-
nant of its rapid clearance.
We have found that injection of excess galactose-Ficoll, a
specific ASGR ligand (20, 27), had little effect on the clear-
ance of IgA1 but sharply decreased the clearance rate of all
three IgA2 allotypes. Our results are in contrast to in vitro
studies that reported the binding of human IgA1 but not
IgA2 to the ASGR on hepatocytes (23, 24). Therefore, we
also studied IgA clearance in mice with ASGR deficiency
due to disruption of the hepatic lectin 2 subunit of the
ASGR (28, 29). We confirmed that these mice are unable
to eliminate radiolabeled asialoorosomucoid (data not
shown). Similar to what we had observed after injection of
galactose-Ficoll, the rate of IgA2 elimination in ASGR2/2
mice resembled that of IgA1 (Fig. 5). The decreased hepatic
uptake of the IgA2 in the presence of galactose-Ficoll in
wild-type mice and in the ASGR2/2 mice (Fig. 6) con-
firmed an essential role for ASGR in mediating the rapid
elimination and hepatic uptake of IgA2. These experimental
findings may explain the clinical observations that the im-
pairment of ASGR function in liver cirrhosis and ALD (30–
32) may result in increased levels of serum IgA2 (2, 3, 7).
Examination of the 24-h clearance patterns of IgA2m(1)
and IgA2m(2) in wild-type and ASGR2/2 mice (Fig. 7)
suggests that the ASGR affects only the initial phase of
elimination. IgA2 surviving the initial rapid elimination is
catabolized at the same rate (t1/2 5 9.5 vs. 10 h) in wild-
type and ASGR2/2 mice. The cause and nature of this
slow exponential phase are unknown. Gel analysis and au-
toradiography of plasma samples obtained during the first
60 min (data not shown) indicated similar rapid elimination
of both dimeric and monomeric IgA2. Furthermore,
monomer-rich IgA2 preparations were eliminated faster,
with a higher percentage of hepatic uptake than the poly-
mer-rich preparation (Fig. 4). Instead, it may be that a por-
tion of the IgA2 did not have an exposed galactose residue
and it is this IgA2 that clears more slowly. Thus, there are
two pathways for the catabolism of IgA2: one through
rapid hepatic uptake by the ASGR, and a second, slower
ASGR-independent pathway. These experimental find-
ings have important clinical implications. Among liver dis-
eases, hepatic cirrhosis is closely linked to ASGR impair-
ment (4, 8, 31), and alterations in IgA metabolism may
explain the shift in the ratio of serum IgA1 to IgA2 seen in
the majority of alcoholics (5–7).
In patients with IgAN, the most common form of glo-
merulonephritis worldwide, altered IgA1 O-linked glyco-
sylation has been implicated as the cause of mesangial IgA1
deposition (33, 34). It is postulated that such alteration
would lead to anomalous handling of IgA1 in IgAN, in-
cluding the failure of normal clearance mechanisms and
mesangial deposition (9, 10). Contrary to this postulate,
we have found that IgA1 lacking the hinge, the site of
O-linked glycosylation, not only failed to clear more slowly
but instead cleared significantly faster than wild-type IgA1
in C57BL/6 mice (Fig. 8). These data would suggest that
the O-glycosylation normally present on IgA1 is not re-
sponsible for rapid clearance. Indeed, the more rapid clear-
ance of IgA1-dHinge suggests that the absence of the hinge
region leads to structural changes that influence catabolism.
Hepatic uptake of IgA1 lacking O-linked glycosylation at
10 min was only 10% (data not shown), a level that is simi-
lar to the original IgA1 molecule. Furthermore, the hinge
deletion affected largely the slow terminal phase by signifi-
cantly (P 5 0.0035) increasing the IgA1 catabolic rate (t1/2 5
10.3 6 0.6 h). Interestingly, this catabolic rate is similar to
that of IgA2 (t1/2 5 9.5 6 0.1 h), which naturally lacks 13
amino acids in the hinge region. Collectively, these turn-
over results are consistent with the clinical observations of
Morell et al. (25) showing that human IgA2 catabolic rate
(t1/2 5 4.5 d) is higher than IgA1 (t1/2 5 5.9 d).
In our studies, the ASGR appeared to play a relatively
minor, but not insignificant, role in the clearance of IgA1.
First, IgA1 lacking the N-linked glycosylation (IgA1-
Ca2,3) cleared significantly (P 5 0.05) less (63% remaining
in circulation) than the unaltered IgA1 (46%) in the first
hour from the blood of wild-type C57BL/6 mice. Simi-
larly, the 1-h clearance value (58%) of IgA1 in ASGR2/2
mice was less than in wild-type mice. Second, measure-
ment of hepatic uptake at 10 min, before any degradation,
revealed significantly (P 5 0.0010) less IgA1-Ca2,3 (5% of
administered dose) than IgA1 (10%) taken up by the liver
of wild-type mice. This is especially significant because the
IgA1-Ca2,3 lacking the N-linked glycosylation consists
predominantly of dimers and higher polymers and there-
fore may be expected to be removed faster with higher
liver uptake than wild-type IgA1 (17). Third, hepatic up-
take of IgA1 at 10 min in ASGR2/2 mice (7%) was signifi-
cantly (P  ,  0.002) less than wild-type C57BL/6 mice.
Thus, it is possible that the influence of N-linked glycosyl-
ation on clearance and hepatic uptake of IgA1 may have
been minimized or masked by the greater role of other re-
ceptor-mediated removal systems in the mouse liver such as
the pIgR. Unlike humans, some species such as the rat and
rabbit rapidly eliminate their polymeric IgA by hepatobil-
iary transport through the pIgR (for a review, see reference
4). Although the mouse eliminates a significant portion
(34%) of serum polymeric IgA through the pIgR hepato-
biliary transport system, the kinetics (8 h) of such elimina-
tion is fairly prolonged and 10 times less efficient than the
rat (15). Studies by Schiff et al. (35) demonstrated that hu-
man IgA may act as a heterovalent ligand that binds to both
the ASGR and pIgR of rat hepatocytes. Our data, demon-
strating slow elimination and low hepatic uptake of IgA1-
Ca2,3 in wild-type mice in a pattern similar to IgA1 in2180 Role of N-Glycans in Blood Clearance and Hepatic Uptake of IgA
ASGR2/2 mice, are consistent with the synergistic action
of ASGR and pIgR in removing IgA from the circulation
of mice. Importantly, the use of two different cooperative
receptors for IgA removal from the circulation observed in
rodents may not be extrapolated to humans due to the lack
of the pIgR on human hepatocytes.
Our results clearly indicate that the N-linked carbohy-
drate residues are important for clearance from the blood
by the ASGR. Since both IgA1 and IgA2 contain N-linked
carbohydrate, the question remains as to why the majority
of the IgA2 but only a small portion of IgA1 is rapidly re-
moved by the ASGR. It is possible that IgA2 binds the
ASGR with a higher affinity than IgA1 as a consequence of
the presence of two additional N-linked glycosylation sites
(Asn166 and Asn337 in CH1 and CH2, respectively) on all
IgA2 allotypes. It is also possible that the N-linked carbo-
hydrates attached to IgA2 differ in structure from that at-
tached to IgA1 and therefore are bound more strongly by
the ASGR. Studies to determine the role of the Asn166 and
Asn337 N-linked glycosylation sites in clearance are in
progress.
Structural analysis of the N-glycans from human IgA1 re-
vealed three major N-linked disialylated biantennary com-
plex–type structures (36, 37). Only a minor amount (7%) of
the N-linked oligosaccharides is triantennary, with an outer
branch substituted with fucose a1–3. Of all the carbohy-
drate structures, it is well established that tetraantennary oli-
gosaccharides, found in asialoorosomucoid, have the highest
binding affinity to the ASGR (38). Thus, the lower affinity
of the biantennary complex–type structure and highly sialy-
lated N-glycans on IgA1 may account for its slow removal
from the circulation by the ASGR. Microheterogeneity of
carbohydrate structure may also explain why a small per-
centage of IgA1 is rapidly cleared. In addition, unlike IgG
in which the N-linked carbohydrates are buried between
the H chains, the N-linked carbohydrates in IgA1 are ex-
posed to the outside (39). Therefore, the N-linked carbo-
hydrates would be expected to be exposed on the surface
and available for recognition by the ASGR (40). The addi-
tional N-linked carbohydrate structures present on IgA2
may be available in combination to bind the ASGR, result-
ing in an increase in the avidity of the IgA2 for the ASGR.
In summary, our results suggest that human IgA1 and
IgA2 isotypes behave differently in the circulation. For the
first time, we have demonstrated that IgA2 allotypes are
rapidly eliminated from the circulation and taken up by the
ASGR expressed on the hepatocytes. At the molecular
level, the N-linked glycans on IgA play an important role
in binding to the ASGR. The increased number of N-linked
glycans on IgA2 may contribute to its rapid elimination
from the circulation, leading to the characteristic distribu-
tion of IgA isotypes observed in humans. These results sug-
gest that abnormal ASGR-mediated clearance and metabo-
lism of IgA in alcoholic liver cirrhosis disease may lead to
enhanced deposition of IgA in liver and kidneys.
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